Greater Glasgow and Clyde Medicines

Restrictions:

Golimumab is included in the Formulary for use in specific patient groups in ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis and axial spondyloarthritis in accordance with SMC advice/local formulary restrictions as detailed in the prescribing notes below.

Prescribing Notes:

Ankylosing spondylitis:

The treatment of severe active ankylosing spondylitis in adults is restricted to use in accordance with the British Society of Rheumatology guidelines. 

For the relevant SMC advice for ankylosing spondylitis click here

Psoriatic Arthritis:

Use in combination with methotrexate, for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate is restricted to specialist use in patients whose disease has not responded to adequate trials of at least two standard DMARDs, administered either individually or in combination. .

For the relevant SMC advice for psoriatic arthritis click here

Rheumatoid Arthritis:

The use in combination with methotrexate, for the treatment of moderate to severe, active rheumatoid arthritis is restricted to use in accordance with the British Society for Rheumatology (BSR) guidelines (2005). 

For relevant SMC advice for rheumatoid arthritis click here

Axial Spondyloarthritis:

The treatment of adults with severe, active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs) is restricted to specialist use.

For the relevant SMC advice for axial spondyloarthritis click here

BNF Link

Restrictions:

Use in the treatment of moderately to severely active ulcerative colitis in adults is restricted to those patients whose disease has responded inadequately to conventional therapy, including corticosteroids, mercaptopurine and azathioprine, or who cannot tolerate, or have medical contraindications for such therapies. See NHSGGC clinical guideline here

Prescribing Notes:

See section 10.1.3 for other indications of golimumab

BNF Link